Tradestie Institutional Equity Comparison Engine

MBX vs BU โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MBX Overall Edge

MBX Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MBX Biosciences, Inc. Common Stock (MBX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MBX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BU at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, MBX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against BU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
MBX N/M vs BU N/M Fwd P/E
Growth & Margin Winner MBX
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner MBX
1Y +120.7% vs -9.1% ยท 52W Pos 61% vs 6%
Options & Structure Winner MBX
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
MBX NASDAQ
MBX Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$53.12
-5.04% 1D
Market Cap $2.8B
1M Return +7.08%
1Y Return +120.69%
Forward P/E N/M
Unified AI Score
45.1 / 100 HOLD
Tech 42.0 Fund 48.0 Flow 50.0 Mom 54.0
BU US Equity
BU
Institutional Equity
$18.17
+0.46% 1D
Market Cap N/A
1M Return -14.04%
1Y Return -9.12%
Forward P/E N/M
Unified AI Score
53.5 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 48.2

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MBX +120.69% BU -9.12% Spread: +15.0 pp (MBX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MBX TTM Op. Margin: 0.0% BU TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBX vs BU. Trailing 12-month operating profitability (MBX 0.0% vs BU N/A) and valuation multiples (MBX N/M vs BU N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MBX (7) vs BU (1)
Institutional Metric MBX BU Criterion Row Winner
Market Capitalization Scale $2.8B N/A Larger Scale MBX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% N/A Higher Growth MBX
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin MBX
Net Profit Margin Profitability 0.0% N/A Higher Margin MBX
Return on Equity (ROE) Capital Efficiency -33.7% N/A Higher ROE MBX
52-Week Range Position Momentum 61% ($23โ€“$73) 6% ($17โ€“$39) Stronger Trend MBX
Beta / 30D Volatility Risk Regime 1.58ฮฒ ยท 66% Vol 3.91ฮฒ ยท 97% Vol Lower Realized Risk MBX
Unified Institutional Score Composite Signal 45.1 / 100 (HOLD) 53.5 / 100 (HOLD) Higher Composite BU

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MBX vs BU Buy Guide
MBX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live MBX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BU UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MBX nor BU registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.